# Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

> **NCT00395031** · PHASE2,PHASE3 · COMPLETED · sponsor: **Manhattan Psychiatric Center** · enrollment: 57 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Ziprasidone

## Key facts

- **NCT ID:** NCT00395031
- **Lead sponsor:** Manhattan Psychiatric Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2011-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395031, "Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00395031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*